Loading…
APO-TRIMIPRAMINE is a brand name for Trimipramine, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
As with other psychotropic drugs, the dosage of APO-TRIMIPRAMINE (trimipramine) should be adapted to the requirements of each individual patient. Treatment should be initiated at the lowest recommended dose and increased gradually, noting carefully the clinical response and any evidence of intolerance.
It should be kept in mind that a lag in therapeutic response usually occurs at the onset of therapy, lasting from several days to a few weeks. Increasing the dosage does not normally shorten this latent period and may increase the incidence of side effects.
Initial Dosage:
Adults: The recommended initial dose is 75 mg daily in two or three divided doses. Initial tolerance may be tested by giving the patient 25 mg in the evening of the first day. The initial dose should be increased by 25 mg increments, usually up to 150 mg daily, preferably by adding to the late afternoon and/or bedtime doses.
In the case of severely depressed patients, a higher initial dose of 100 mg daily in two or three divided doses may be indicated. The usual optimal dose is 150 to 200 mg daily, but some patients may require up to 300 mg daily, depending on tolerance and response of each individual patient.
5 to 25 mg and, after 45 minutes, examine the patient sitting and standing to check for orthostatic hypotension. Initial doses should usually be no more than 50 mg a day in divided doses, with weekly increments of no more than 25 mg a week, leading to a usual therapeutic dose range of 50 to 150 mg a day.
Blood pressure and cardiac rhythm must be checked frequently, particularly in patients who have unstable cardiovascular function.
Maintenance Dosage:
Once a satisfactory response has been obtained, the dosage should be adjusted to the lowest level required to maintain symptomatic relief. Medication should be continued for the expected duration of the depressive episode in order to minimize the possibility of relapse following clinical improvement.
10 When a maintenance dosage has been established as described above, trimipramine may be administered in a single dose before bedtime provided such a dosage regimen is well tolerated. 5 Description: Trimipramine maleate is a white or almost white, crystalline powder.
It is slightly soluble in water and in ethanol; freely soluble in chloroform; and practically insoluble in ether.
Composition Tablets:
In addition to trimipramine maleate, each tablet contains the non-medicinal ingredients microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide and FD&C red #3.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Trimipramine in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Capsules:
In addition to trimipramine maleate, each capsule contains the non-medicinal ingredients lactose, croscarmellose sodium, stearic acid, magnesium stearate, gelatin, sodium lauryl sulfate, sodium metabisulfite, FD&C red #3, D&C yellow #10, titanium dioxide and 12 FD&C blue #1.
The edible black printing ink on the capsule shell contains the non-medicinal ingredients synthetic black iron oxide, FD&C blue #1, FD&C blue #2, FD&C red #40, D&C yellow #10, pharmaceutical glaze, alcohol and propylene glycol. Stability and Storage Recommendations Protect from light.
Store at controlled room temperature 15-30°C (59-86°F). 5 mg of trimipramine. APO-TRIMIPRAMINE (Trimipramine Tablets BP), 25 mg: each round, pink, biconvex, film- coated tablet, engraved "25 on one side, contains trimipramine maleate equivalent to 25 mg of trimipramine.
APO-TRIMIPRAMINE (Trimipramine Tablets BP), 50 mg: each round, pink, biconvex, film- coated tablet engraved "50" on one side contains trimipramine maleate equivalent to 50 mg of trimipramine. APO-TRIMIPRAMINE (Trimipramine Tablets BP), 100 mg: each round, pink, biconvex, film- coated tablet scored and engraved "100" on one side contains trimipramine maleate equivalent to 100 mg of trimipramine.
Capsules APO-TRIMIPRAMINE (Trimipramine Capsules), 75 mg: each hard gelatin capsule with buff body and pink cap, printed "75", contains trimipramine maleate equivalent to 75 mg of trimipramine. APO-TRIMIPRAMINE tablets and capsules are available in bottles of 100, 500 and 1000.
13 PHARMACOLOGY Like other tricyclic antidepressants trimipramine antagonizes reserpine induced ptosis, hypothermia and depression in mice and rats and post electroshock depression in the rabbit and in the rat. It potentiates the narcotic effect of ether and hexobarbital and depresses spontaneous activity in mice, but does not cause catalepsy and does not block significantly conditioned avoidance responses.
Trimipramine protects against maximal electroshock-induced convulsions, but lowers the threshold for metrazol-induced convulsions. In 'in vitro' tests, anti-serotonin and antihistaminic activities have been demonstrated. Trimipramine also possesses antiemetic and analgesic properties.
Like other tricyclic drugs, trimipramine potentiates the pressor effect of directly acting sympathomimetic amines. The drug also has anticholinergic properties. Trimipramine lowers the blood pressure in anesthetized dogs and induces tachycardia of short duration.
Like other tricyclic agents, trimipramine exerts a quinidine-like myocardial depressant effect in chloralose-anesthetized dogs.
TOXICOLOGY Acute Toxicity:
The LD50 of trimipramine in the mouse is 42 mg/kg intravenously, 425 mg/kg per os, 285 mg/kg subcutaneously, and […]